Evaluation of lorcainide, a new anti-arrhythmic agent.
A new anti-arrhythmic agent, lorcainide, has been compared with lignocaine in patients with acute myocardial infarction. Lorcainide has been shown to be as effective as lignocaine in suppressing ventricular ectopy. Lorcainide is unusually free of side-effects and has the great advantage over lignocaine of being effective when given orally.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D044482:Benzeneacetamides; D004341:Drug Evaluation; D006801:Humans; D008012:Lidocaine / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D044482:Benzeneacetamides; D010880:Piperidines; D008012:Lidocaine; C015970:lorcainide